Developing world gets tiny share of cancer spend

Key points
- The developing world sees only 5 percent of the world's spending on cancer treatment, despite accounting for around half of new cases and nearly two-thirds of cancer deaths, a report published on Monday said.
- The incidence of cancer, once thought to be a disease of the affluent, is rising in poor countries, and there is an estimated $217 billion shortfall in funding for cancer treatment globally, according to a report by the Economist Intelligence Unit.
- The study estimated that the economic burden of new cancer cases would reach $305 billion this year, and that by 2020 there would be 16.8 million new cancer cases a year worldwide, compared to 12.9 million now.
- The report was released by the Lance Armstrong Foundation, set up by the 7-time winner of the Tour de France after his own battle with testicular cancer.
The developing world sees only 5 percent of the world's spending on cancer treatment, despite accounting for around half of new cases and nearly two-thirds of cancer deaths, a report published on Monday said.
The incidence of cancer, once thought to be a disease of the affluent, is rising in poor countries, and there is an estimated $217 billion shortfall in funding for cancer treatment globally, according to a report by the Economist Intelligence Unit.
The study estimated that the economic burden of new cancer cases would reach $305 billion this year, and that by 2020 there would be 16.8 million new cancer cases a year worldwide, compared to 12.9 million now.
The report was released by the Lance Armstrong Foundation, set up by the 7-time winner of the Tour de France after his own battle with testicular cancer.
Speaking at a global cancer conference organised by the foundation in Dublin, Irish Health Minister Mary Harney said she would seek a total ban on sunbeds to reduce the risk of skin cancer.
"Clearly, any decisions we make here will have to get EU approval," she said. "It may well be that, in the interests of public health, such approval could be forthcoming."
DUBLIN (Reuters)
Written and revised by
Gerald Hurowitz, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsHDAC inhibitor targets triple negative breast cancer
The histone de-acetylase (HDAC) inhibitor panobinostat is able to target and destroy triple negative breast cancer, reveals a new study published in BioMed Central's open access journal Breast Cancer Research.…
21 May 2012
NewsArray shares rise on lung cancer, melanoma results
Array BioPharma Inc's experimental lung cancer drug, selumetinib, w as shown to increase survival by an additional 4.2 months over chemotherapy alone, according to new data released on Wednesday. The company also…
17 May 2012
NewsTiny hitchhikers attack cancer cells
Nanotechnology offers powerful new possibilities for targeted cancer therapies, but the design challenges are many. Northwestern University scientists now are the first to develop a simple but specialized nanoparticle…
6 April 2012



